| Bioactivity | 4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM. | ||||||||||||
| Target | IC50: 13.5 μM (eIF4E-eIF4G) | ||||||||||||
| Invitro | 4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner[1]. | ||||||||||||
| In Vivo | 4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death[1]. | ||||||||||||
| Name | 4E2RCat | ||||||||||||
| CAS | 432499-63-3 | ||||||||||||
| Formula | C22H14ClNO4S2 | ||||||||||||
| Molar Mass | 455.93 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cencic R, et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9. |